HyperBio Therapeutics ApS: Financial statements 2023
CVR: 41244909
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
HyperBio Therapeutics ApS (CVR 41244909) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -74,484 and a net result of DKK -972,747 compared with DKK -7,656,366 the year before. Equity in the 2023 report amounted to DKK 739,784. The solvency ratio was 5%.
- Gross Profit
- DKK -74,484
- Profit/Loss
- DKK -972,747
- Equity
- DKK 739,784
- Total Assets
- DKK 14,654,028
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -74 t. | -973 t. | 740 t. | - |
| 2022 | - | -8.6 mio. | -7.7 mio. | -2.3 mio. | - |
| 2021 | - | -12.9 mio. | -10.6 mio. | 5.4 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
HyperBio Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -8,628,935, and the net result was DKK -7,656,366.
As of June 9, 2023, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has stepped down as auditor of HyperBio Therapeutics ApS.
About HyperBio Therapeutics ApS
HyperBio Therapeutics ApS was a Danish company of the type Anpartsselskab based in Vejle Øst, founded in 2020. The company has been dissolved on 14 January 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. In 2023, the company reported a gross profit of DKK -74,484 and a net result of DKK -972,747 compared with DKK -7,656,366 the year before. Equity in the 2023 report amounted to DKK 739,784.